NewAmsterdam Pharma Company N.V. (NAMS) Stock Competitors & Peer Comparison
See (NAMS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NAMS | $33.12 | +4.45% | 3.8B | -18.04 | -$1.78 | N/A |
| NVO | $43.84 | +2.14% | 186.7B | 9.86 | $4.26 | +4.27% |
| VRTX | $446.19 | +4.96% | 108.7B | 25.46 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $626.91 | +3.98% | 63.8B | 15.12 | $40.94 | +0.59% |
| ARGX | $849.49 | +5.90% | 50.3B | 36.16 | $22.49 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $304.19 | +6.32% | 39.1B | 73.36 | $3.99 | N/A |
| RVMD | $155.60 | +2.83% | 33.2B | -21.97 | -$7.10 | N/A |
| RPRX | $55.09 | +2.01% | 23.6B | 28.93 | $1.90 | +1.65% |
Stock Comparison
NAMS vs NVO Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, NVO has a market cap of 186.7B. Regarding current trading prices, NAMS is priced at $33.12, while NVO trades at $43.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas NVO's P/E ratio is 9.86. In terms of profitability, NAMS's ROE is -0.30%, compared to NVO's ROE of +0.66%. Regarding short-term risk, NAMS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check NVO's competition here
NAMS vs VRTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, VRTX has a market cap of 108.7B. Regarding current trading prices, NAMS is priced at $33.12, while VRTX trades at $446.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas VRTX's P/E ratio is 25.46. In terms of profitability, NAMS's ROE is -0.30%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, NAMS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check VRTX's competition here
NAMS vs VRNA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NAMS is priced at $33.12, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NAMS's ROE is -0.30%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, NAMS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check VRNA's competition here
NAMS vs REGN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, REGN has a market cap of 63.8B. Regarding current trading prices, NAMS is priced at $33.12, while REGN trades at $626.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas REGN's P/E ratio is 15.12. In terms of profitability, NAMS's ROE is -0.30%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NAMS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check REGN's competition here
NAMS vs ARGX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, NAMS is priced at $33.12, while ARGX trades at $849.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ARGX's P/E ratio is 36.16. In terms of profitability, NAMS's ROE is -0.30%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, NAMS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ARGX's competition here
NAMS vs SGEN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NAMS is priced at $33.12, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NAMS's ROE is -0.30%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NAMS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check SGEN's competition here
NAMS vs ALNY Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ALNY has a market cap of 39.1B. Regarding current trading prices, NAMS is priced at $33.12, while ALNY trades at $304.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ALNY's P/E ratio is 73.36. In terms of profitability, NAMS's ROE is -0.30%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, NAMS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check ALNY's competition here
NAMS vs RVMD Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RVMD has a market cap of 33.2B. Regarding current trading prices, NAMS is priced at $33.12, while RVMD trades at $155.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RVMD's P/E ratio is -21.97. In terms of profitability, NAMS's ROE is -0.30%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NAMS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RVMD's competition here
NAMS vs RPRX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, NAMS is priced at $33.12, while RPRX trades at $55.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RPRX's P/E ratio is 28.93. In terms of profitability, NAMS's ROE is -0.30%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, NAMS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RPRX's competition here
NAMS vs UTHR Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, NAMS is priced at $33.12, while UTHR trades at $548.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas UTHR's P/E ratio is 20.31. In terms of profitability, NAMS's ROE is -0.30%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NAMS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check UTHR's competition here
NAMS vs INSM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, INSM has a market cap of 22.5B. Regarding current trading prices, NAMS is priced at $33.12, while INSM trades at $104.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas INSM's P/E ratio is -18.03. In terms of profitability, NAMS's ROE is -0.30%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NAMS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check INSM's competition here
NAMS vs BNTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BNTX has a market cap of 22.4B. Regarding current trading prices, NAMS is priced at $33.12, while BNTX trades at $89.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BNTX's P/E ratio is -14.97. In terms of profitability, NAMS's ROE is -0.30%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NAMS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check BNTX's competition here
NAMS vs ROIV Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, NAMS is priced at $33.12, while ROIV trades at $29.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ROIV's P/E ratio is -53.15. In terms of profitability, NAMS's ROE is -0.30%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NAMS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ROIV's competition here
NAMS vs BGNE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NAMS is priced at $33.12, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NAMS's ROE is -0.30%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NAMS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check BGNE's competition here
NAMS vs INCY Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, NAMS is priced at $33.12, while INCY trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas INCY's P/E ratio is 13.84. In terms of profitability, NAMS's ROE is -0.30%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NAMS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check INCY's competition here
NAMS vs MRNA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MRNA has a market cap of 19.5B. Regarding current trading prices, NAMS is priced at $33.12, while MRNA trades at $51.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MRNA's P/E ratio is -6.02. In terms of profitability, NAMS's ROE is -0.30%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, NAMS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check MRNA's competition here
NAMS vs DNA-WT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NAMS is priced at $33.12, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NAMS's ROE is -0.30%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NAMS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check DNA-WT's competition here
NAMS vs NBIX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, NBIX has a market cap of 16.6B. Regarding current trading prices, NAMS is priced at $33.12, while NBIX trades at $168.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas NBIX's P/E ratio is 25.40. In terms of profitability, NAMS's ROE is -0.30%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, NAMS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check NBIX's competition here
NAMS vs GMAB Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, GMAB has a market cap of 14.7B. Regarding current trading prices, NAMS is priced at $33.12, while GMAB trades at $24.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas GMAB's P/E ratio is 18.23. In terms of profitability, NAMS's ROE is -0.30%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NAMS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check GMAB's competition here
NAMS vs JAZZ Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, NAMS is priced at $33.12, while JAZZ trades at $239.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas JAZZ's P/E ratio is 1924.42. In terms of profitability, NAMS's ROE is -0.30%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, NAMS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check JAZZ's competition here
NAMS vs ASND Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ASND has a market cap of 13.4B. Regarding current trading prices, NAMS is priced at $33.12, while ASND trades at $220.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ASND's P/E ratio is 24.58. In terms of profitability, NAMS's ROE is -0.30%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NAMS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ASND's competition here
NAMS vs EXEL Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, NAMS is priced at $33.12, while EXEL trades at $52.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas EXEL's P/E ratio is 17.09. In terms of profitability, NAMS's ROE is -0.30%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NAMS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check EXEL's competition here
NAMS vs BBIO Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, NAMS is priced at $33.12, while BBIO trades at $67.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BBIO's P/E ratio is -17.51. In terms of profitability, NAMS's ROE is -0.30%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NAMS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check BBIO's competition here
NAMS vs KRTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NAMS is priced at $33.12, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NAMS's ROE is -0.30%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NAMS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check KRTX's competition here
NAMS vs IONS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, NAMS is priced at $33.12, while IONS trades at $75.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas IONS's P/E ratio is -36.73. In terms of profitability, NAMS's ROE is -0.30%, compared to IONS's ROE of -0.59%. Regarding short-term risk, NAMS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check IONS's competition here
NAMS vs AXSM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, NAMS is priced at $33.12, while AXSM trades at $235.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas AXSM's P/E ratio is -62.60. In terms of profitability, NAMS's ROE is -0.30%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NAMS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check AXSM's competition here
NAMS vs SMMT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, NAMS is priced at $33.12, while SMMT trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas SMMT's P/E ratio is -9.48. In terms of profitability, NAMS's ROE is -0.30%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, NAMS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check SMMT's competition here
NAMS vs RNAM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NAMS is priced at $33.12, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NAMS's ROE is -0.30%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NAMS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RNAM's competition here
NAMS vs MDGL Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MDGL has a market cap of 11.3B. Regarding current trading prices, NAMS is priced at $33.12, while MDGL trades at $496.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MDGL's P/E ratio is -36.21. In terms of profitability, NAMS's ROE is -0.30%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, NAMS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check MDGL's competition here
NAMS vs BMRN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, NAMS is priced at $33.12, while BMRN trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BMRN's P/E ratio is 39.32. In terms of profitability, NAMS's ROE is -0.30%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NAMS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check BMRN's competition here
NAMS vs ARWR Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ARWR has a market cap of 10.2B. Regarding current trading prices, NAMS is priced at $33.12, while ARWR trades at $75.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ARWR's P/E ratio is -31.96. In terms of profitability, NAMS's ROE is -0.30%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NAMS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check ARWR's competition here
NAMS vs RXDX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NAMS is priced at $33.12, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NAMS's ROE is -0.30%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NAMS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RXDX's competition here
NAMS vs KRYS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, NAMS is priced at $33.12, while KRYS trades at $309.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas KRYS's P/E ratio is 40.35. In terms of profitability, NAMS's ROE is -0.30%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NAMS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check KRYS's competition here
NAMS vs CYTK Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, NAMS is priced at $33.12, while CYTK trades at $72.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CYTK's P/E ratio is -10.32. In terms of profitability, NAMS's ROE is -0.30%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NAMS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CYTK's competition here
NAMS vs IMGN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NAMS is priced at $33.12, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NAMS's ROE is -0.30%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NAMS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check IMGN's competition here
NAMS vs BPMC Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NAMS is priced at $33.12, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NAMS's ROE is -0.30%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, NAMS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check BPMC's competition here
NAMS vs HALO Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, NAMS is priced at $33.12, while HALO trades at $71.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas HALO's P/E ratio is 24.50. In terms of profitability, NAMS's ROE is -0.30%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NAMS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check HALO's competition here
NAMS vs CERE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NAMS is priced at $33.12, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CERE's P/E ratio is -16.47. In terms of profitability, NAMS's ROE is -0.30%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NAMS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CERE's competition here
NAMS vs TECH Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, NAMS is priced at $33.12, while TECH trades at $52.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas TECH's P/E ratio is 72.64. In terms of profitability, NAMS's ROE is -0.30%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NAMS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check TECH's competition here
NAMS vs CORT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, NAMS is priced at $33.12, while CORT trades at $74.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CORT's P/E ratio is 207.57. In terms of profitability, NAMS's ROE is -0.30%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NAMS is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check CORT's competition here
NAMS vs IBRX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, NAMS is priced at $33.12, while IBRX trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas IBRX's P/E ratio is -8.45. In terms of profitability, NAMS's ROE is -0.30%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, NAMS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check IBRX's competition here
NAMS vs MTSR Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NAMS is priced at $33.12, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NAMS's ROE is -0.30%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, NAMS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check MTSR's competition here
NAMS vs ALKS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ALKS has a market cap of 7.1B. Regarding current trading prices, NAMS is priced at $33.12, while ALKS trades at $43.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ALKS's P/E ratio is 47.51. In terms of profitability, NAMS's ROE is -0.30%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, NAMS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ALKS's competition here
NAMS vs MRUS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NAMS is priced at $33.12, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NAMS's ROE is -0.30%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, NAMS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check MRUS's competition here
NAMS vs PCVX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, NAMS is priced at $33.12, while PCVX trades at $48.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas PCVX's P/E ratio is -6.81. In terms of profitability, NAMS's ROE is -0.30%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NAMS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check PCVX's competition here
NAMS vs ACLX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NAMS is priced at $33.12, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NAMS's ROE is -0.30%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NAMS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ACLX's competition here
NAMS vs LEGN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, LEGN has a market cap of 6.7B. Regarding current trading prices, NAMS is priced at $33.12, while LEGN trades at $34.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas LEGN's P/E ratio is -26.07. In terms of profitability, NAMS's ROE is -0.30%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, NAMS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check LEGN's competition here
NAMS vs NUVL Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, NUVL has a market cap of 6.6B. Regarding current trading prices, NAMS is priced at $33.12, while NUVL trades at $93.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas NUVL's P/E ratio is -14.87. In terms of profitability, NAMS's ROE is -0.30%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NAMS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check NUVL's competition here
NAMS vs RETA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NAMS is priced at $33.12, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RETA's P/E ratio is -66.29. In terms of profitability, NAMS's ROE is -0.30%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NAMS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RETA's competition here
NAMS vs IMVT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, IMVT has a market cap of 6.4B. Regarding current trading prices, NAMS is priced at $33.12, while IMVT trades at $32.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas IMVT's P/E ratio is -11.25. In terms of profitability, NAMS's ROE is -0.30%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NAMS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check IMVT's competition here
NAMS vs CNTA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, NAMS is priced at $33.12, while CNTA trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CNTA's P/E ratio is -22.39. In terms of profitability, NAMS's ROE is -0.30%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NAMS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CNTA's competition here
NAMS vs TGTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, NAMS is priced at $33.12, while TGTX trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas TGTX's P/E ratio is 14.02. In terms of profitability, NAMS's ROE is -0.30%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, NAMS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check TGTX's competition here
NAMS vs PTGX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, NAMS is priced at $33.12, while PTGX trades at $102.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas PTGX's P/E ratio is -52.71. In terms of profitability, NAMS's ROE is -0.30%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NAMS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check PTGX's competition here
NAMS vs KYMR Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, KYMR has a market cap of 6B. Regarding current trading prices, NAMS is priced at $33.12, while KYMR trades at $74.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas KYMR's P/E ratio is -20.45. In terms of profitability, NAMS's ROE is -0.30%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NAMS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check KYMR's competition here
NAMS vs ABVX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ABVX has a market cap of 5.9B. Regarding current trading prices, NAMS is priced at $33.12, while ABVX trades at $102.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ABVX's P/E ratio is -16.79. In terms of profitability, NAMS's ROE is -0.30%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NAMS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check ABVX's competition here
NAMS vs PRAX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, PRAX has a market cap of 5.9B. Regarding current trading prices, NAMS is priced at $33.12, while PRAX trades at $268.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas PRAX's P/E ratio is -20.82. In terms of profitability, NAMS's ROE is -0.30%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NAMS is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check PRAX's competition here
NAMS vs RYTM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, NAMS is priced at $33.12, while RYTM trades at $87.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RYTM's P/E ratio is -27.06. In terms of profitability, NAMS's ROE is -0.30%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, NAMS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RYTM's competition here
NAMS vs PTCT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, NAMS is priced at $33.12, while PTCT trades at $70.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas PTCT's P/E ratio is -27.04. In terms of profitability, NAMS's ROE is -0.30%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, NAMS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check PTCT's competition here
NAMS vs CDTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NAMS is priced at $33.12, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NAMS's ROE is -0.30%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, NAMS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CDTX's competition here
NAMS vs ABCM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NAMS is priced at $33.12, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NAMS's ROE is -0.30%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NAMS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ABCM's competition here
NAMS vs COGT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, NAMS is priced at $33.12, while COGT trades at $32.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas COGT's P/E ratio is -14.87. In terms of profitability, NAMS's ROE is -0.30%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NAMS is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check COGT's competition here
NAMS vs ISEE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NAMS is priced at $33.12, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NAMS's ROE is -0.30%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NAMS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ISEE's competition here
NAMS vs BLTE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, NAMS is priced at $33.12, while BLTE trades at $145.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BLTE's P/E ratio is -53.82. In terms of profitability, NAMS's ROE is -0.30%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, NAMS is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check BLTE's competition here
NAMS vs SRRK Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, NAMS is priced at $33.12, while SRRK trades at $45.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas SRRK's P/E ratio is -12.94. In terms of profitability, NAMS's ROE is -0.30%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NAMS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check SRRK's competition here
NAMS vs APLS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NAMS is priced at $33.12, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas APLS's P/E ratio is 38.35. In terms of profitability, NAMS's ROE is -0.30%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NAMS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check APLS's competition here
NAMS vs APGE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, NAMS is priced at $33.12, while APGE trades at $89.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas APGE's P/E ratio is -19.44. In terms of profitability, NAMS's ROE is -0.30%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NAMS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check APGE's competition here
NAMS vs CRSP Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, NAMS is priced at $33.12, while CRSP trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CRSP's P/E ratio is -8.44. In terms of profitability, NAMS's ROE is -0.30%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, NAMS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check CRSP's competition here
NAMS vs LQDA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, LQDA has a market cap of 5B. Regarding current trading prices, NAMS is priced at $33.12, while LQDA trades at $63.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas LQDA's P/E ratio is 327.59. In terms of profitability, NAMS's ROE is -0.30%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, NAMS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check LQDA's competition here
NAMS vs FBIOX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, FBIOX has a market cap of 4.9B. Regarding current trading prices, NAMS is priced at $33.12, while FBIOX trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas FBIOX's P/E ratio is N/A. In terms of profitability, NAMS's ROE is -0.30%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, NAMS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check FBIOX's competition here
NAMS vs CGON Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, NAMS is priced at $33.12, while CGON trades at $56.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CGON's P/E ratio is -23.26. In terms of profitability, NAMS's ROE is -0.30%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NAMS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check CGON's competition here
NAMS vs TERN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NAMS is priced at $33.12, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas TERN's P/E ratio is -51.41. In terms of profitability, NAMS's ROE is -0.30%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NAMS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check TERN's competition here
NAMS vs LGND Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, NAMS is priced at $33.12, while LGND trades at $235.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas LGND's P/E ratio is 30.56. In terms of profitability, NAMS's ROE is -0.30%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NAMS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check LGND's competition here
NAMS vs MIRM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, NAMS is priced at $33.12, while MIRM trades at $94.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MIRM's P/E ratio is -6.75. In terms of profitability, NAMS's ROE is -0.30%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NAMS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check MIRM's competition here
NAMS vs FOLD Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NAMS is priced at $33.12, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NAMS's ROE is -0.30%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NAMS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check FOLD's competition here
NAMS vs AKRO Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NAMS is priced at $33.12, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NAMS's ROE is -0.30%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, NAMS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check AKRO's competition here
NAMS vs ALPN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NAMS is priced at $33.12, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NAMS's ROE is -0.30%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NAMS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ALPN's competition here
NAMS vs SYRE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, NAMS is priced at $33.12, while SYRE trades at $78.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas SYRE's P/E ratio is -34.60. In terms of profitability, NAMS's ROE is -0.30%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NAMS is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check SYRE's competition here
NAMS vs CAI Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, NAMS is priced at $33.12, while CAI trades at $17.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CAI's P/E ratio is -5.61. In terms of profitability, NAMS's ROE is -0.30%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NAMS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check CAI's competition here
NAMS vs CELC Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, NAMS is priced at $33.12, while CELC trades at $90.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CELC's P/E ratio is -22.81. In terms of profitability, NAMS's ROE is -0.30%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NAMS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check CELC's competition here
NAMS vs OPT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NAMS is priced at $33.12, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas OPT's P/E ratio is -1.52. In terms of profitability, NAMS's ROE is -0.30%, compared to OPT's ROE of +1.09%. Regarding short-term risk, NAMS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check OPT's competition here
NAMS vs XENE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, NAMS is priced at $33.12, while XENE trades at $53.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas XENE's P/E ratio is -11.37. In terms of profitability, NAMS's ROE is -0.30%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NAMS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check XENE's competition here
NAMS vs TVTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, NAMS is priced at $33.12, while TVTX trades at $46.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas TVTX's P/E ratio is -90.40. In terms of profitability, NAMS's ROE is -0.30%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NAMS is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check TVTX's competition here
NAMS vs MRTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NAMS is priced at $33.12, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NAMS's ROE is -0.30%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NAMS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check MRTX's competition here
NAMS vs ERAS Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ERAS has a market cap of 4.1B. Regarding current trading prices, NAMS is priced at $33.12, while ERAS trades at $13.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ERAS's P/E ratio is -14.17. In terms of profitability, NAMS's ROE is -0.30%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NAMS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check ERAS's competition here
NAMS vs MANE Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, MANE has a market cap of 4B. Regarding current trading prices, NAMS is priced at $33.12, while MANE trades at $101.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas MANE's P/E ratio is -36.37. In terms of profitability, NAMS's ROE is -0.30%, compared to MANE's ROE of -0.95%. Regarding short-term risk, NAMS is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check MANE's competition here
NAMS vs EWTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, NAMS is priced at $33.12, while EWTX trades at $37.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas EWTX's P/E ratio is -21.81. In terms of profitability, NAMS's ROE is -0.30%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NAMS is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check EWTX's competition here
NAMS vs VCYT Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, NAMS is priced at $33.12, while VCYT trades at $49.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas VCYT's P/E ratio is 45.08. In terms of profitability, NAMS's ROE is -0.30%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, NAMS is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check VCYT's competition here
NAMS vs CPRX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, NAMS is priced at $33.12, while CPRX trades at $31.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CPRX's P/E ratio is 18.08. In terms of profitability, NAMS's ROE is -0.30%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NAMS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CPRX's competition here
NAMS vs RYZB Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NAMS is priced at $33.12, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NAMS's ROE is -0.30%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NAMS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check RYZB's competition here
NAMS vs CBAY Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NAMS is priced at $33.12, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NAMS's ROE is -0.30%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NAMS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CBAY's competition here
NAMS vs ACAD Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, NAMS is priced at $33.12, while ACAD trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas ACAD's P/E ratio is 9.70. In terms of profitability, NAMS's ROE is -0.30%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NAMS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check ACAD's competition here
NAMS vs KNSA Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, NAMS is priced at $33.12, while KNSA trades at $49.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas KNSA's P/E ratio is 52.58. In terms of profitability, NAMS's ROE is -0.30%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, NAMS is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check KNSA's competition here
NAMS vs DNTH Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, NAMS is priced at $33.12, while DNTH trades at $82.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas DNTH's P/E ratio is -20.09. In terms of profitability, NAMS's ROE is -0.30%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NAMS is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check DNTH's competition here
NAMS vs SWTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NAMS is priced at $33.12, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NAMS's ROE is -0.30%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, NAMS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check SWTX's competition here
NAMS vs CRNX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, CRNX has a market cap of 3.5B. Regarding current trading prices, NAMS is priced at $33.12, while CRNX trades at $34.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas CRNX's P/E ratio is -6.44. In terms of profitability, NAMS's ROE is -0.30%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NAMS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check CRNX's competition here
NAMS vs VKTX Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, NAMS is priced at $33.12, while VKTX trades at $29.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas VKTX's P/E ratio is -7.07. In terms of profitability, NAMS's ROE is -0.30%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, NAMS is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check VKTX's competition here
NAMS vs DNLI Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, NAMS is priced at $33.12, while DNLI trades at $20.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas DNLI's P/E ratio is -6.83. In terms of profitability, NAMS's ROE is -0.30%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NAMS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check DNLI's competition here
NAMS vs BEAM Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, NAMS is priced at $33.12, while BEAM trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas BEAM's P/E ratio is -60.31. In terms of profitability, NAMS's ROE is -0.30%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, NAMS is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for NAMS.Check BEAM's competition here
NAMS vs DYN Comparison June 2026
NAMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAMS stands at 3.8B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, NAMS is priced at $33.12, while DYN trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAMS currently has a P/E ratio of -18.04, whereas DYN's P/E ratio is -5.71. In terms of profitability, NAMS's ROE is -0.30%, compared to DYN's ROE of -0.58%. Regarding short-term risk, NAMS is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for NAMS.Check DYN's competition here